mfluidx

mFluiDx Aims to Develop the World's Lowest-Cost Automated Point-of-Care DNA Diagnostic Assay for Small Clinics. In small clinics, such as primary care outpatient facilities, disease diagnosis is typically performed by observing symptoms or using strip antibody tests. However, these methods have lower sensitivity compared to DNA diagnostics. Due to high costs and the need to send tests off-site, highly sensitive molecular DNA tests (PCR) are not frequently used, with turnaround times being very short (a few days). mFluiDx, an emerging company from UC Berkeley funded by the Gates Foundation, focuses on low-cost microfluidic diagnostic technology capable of conducting on-site multi-target isothermal DNA detection for infectious diseases. It is easy to operate and costs about 100 times less than PCR devices. Our goal is to create a test that can be deployed in decentralized settings, as simple and inexpensive as paper-based tests, yet offers DNA-level sensitivity for on-site diagnosis.